Chart Scan – Dec 30, 2022

Chart Scan – Dec 30, 2022

ADMP – Adamis Pharmaceuticals Corp.

AGLE – Aeglea BioTherapeutics, Inc.

ANGI – Angie’s List Inc.

APDN – Applied DNA Sciences Inc.

AVCT – American Virtual Cloud Technologies Inc.

BITF – Bitfarms Ltd.

CDLX – Cardlytics, Inc.

CELU – Celularity Inc.

CHRS – Coherus BioSciences Inc.

CIFR – Cipher Mining Inc.

CNTA – Centessa Pharmaceuticals Plc

DBGI – Digital Brands Group Inc.

DRMA – Dermata Therapeutics Inc.

DTIL – Precision BioSciences Inc.

EVAX – Evaxion Biotech A/S

EVGO – EVgo Inc.

EZGO – EZGO Technologies Ltd.

GERN – Geron Corp.

GRNA – GreenLight Biosciences Inc.

HGEN – Humanigen, Inc.

HOOK – HOOKIPA Pharma Inc.

IDEX – Ideanomics, Inc.

INFI – Infinity Pharmaceuticals, Inc.

INVZ – Innoviz Technologies Ltd.

KPLT – Katapult Holdings, Inc.

KPRX – Kiora Pharmaceuticals, Inc.

LE – Lands End Inc.

LTRPA – Liberty TripAdvisor Holdings, Inc.

MEDS – Trxade Group Inc.

MGNX – MacroGenics Inc.

MREO – Mereo BioPharma Group Plc

MVIS – Microvision, Inc.

MVST – Microvast Holdings, Inc.

NEXI – Neximmune Inc.

NKTR – Nektar Therapeutics

NKTX – Nkarta Inc.

NOVN – Novan, Inc.

NVTS – Navitas Semiconductor Corporation

OIG – Orbital Infrastructure Group, Inc.

OPEN – Opendoor Technologies Inc.

PGEN – Precigen, Inc.

PIRS – Pieris Pharmaceuticals Inc.

QNCX – Quince Therapeutics, Inc.

RIDE – Lordstown Motors Corp.

RIGL – Rigel Pharmaceuticals Inc.

SDIG – Stronghold Digital Mining Inc.

SESN – Sesen Bio, Inc.

SMFR – Sema4 Holdings Corp.

SOUN – SoundHound AI Inc.

SWVL – Swvl Holdings Corp

TBLA – Taboola.com Ltd.

TBLT – ToughBuilt Industries, Inc.

TSHA – Taysha Gene Therapies Inc.

VISL – Vislink Technologies, Inc.

VMEO – Vimeo Inc.

VRM – Vroom Inc.

WETG – WeTrade Group

XERS – Xeris Pharmaceuticals Inc.

XXII – 22nd Century Group, Inc.

Disclaimer:
We have not received any form of compensation for the generation of this blog

Any type of reproduction, copying or distribution of the material in this email is prohibited without a written consent from the site owner.

Disclaimer- By reading our newsletter you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold us, our editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook and chat. We do not advise any reader take any specific action. Our website, newsletter, twitter, Facebook and chat are for informational and educational purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter, twitter, Facebook and on our website may be based on EOD or intraday data. We may be compensated for the production, release and awareness of this newsletter. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. Our emails may contain Forward Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters, twitter, Facebook our website and chat is believed to be accurate and correct, but has not been independently verified. The information in our disclaimers is subject to change at any time without notice.

We are not held liable or responsible for the information in press releases issued by the companies discussed in these blog. Please do your own due diligence.

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments